Skip to main content

Select Drug Profiles

Payers' Guide, FDA Approvals
Xeljanz (Tofacitinib) Receives Expanded Indication, Becoming the First Oral JAK Inhibitor Approved for Ulcerative Colitis
Loretta Fala
Read More
FDA Approvals, Oncology Overview, Payers' Guide, Oncology
New Indications Approved by the FDA in 2018 for Oncology Drugs
Dalia Buffery, MA, ABD
Read More
Breast Cancer, FDA Approvals, In the News, Oncology
FDA Approves First Hormonal-Based Therapy for Men with Advanced or Metastatic Breast Cancer
Read More
Breast Cancer, FDA Approvals, In the News, Oncology
Proposed Landmark Policy Changes to Modernize Mammography and Raise Breast Density Awareness
Read More
FDA Approvals, In the News, Lung Cancer, Oncology
FDA Approves Tecentriq plus Chemotherapy for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer
Read More
FDA Approvals, In the News
FDA Approves Tecentriq plus Abraxane—First Immunotherapy for PD-L1– Positive Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Read More
FDA Approvals, In the News
March 08, 2019 - FDA Approvals, News & Updates
Read More
Practice Management
Economic Implications of Inpatient versus Outpatient Autologous Transplant for Patients with Multiple Myeloma
Chase Doyle
Chase Doyle
Read More
Practice Management
Inpatient Costs for Children and Young Adults with Acute Lymphoblastic Leukemia Higher at Specialized Cancer Centers, but for a Good Reason?
Chase Doyle
Chase Doyle
Read More
In the Literature, Oncology
Ibrutinib Superior to Standard Chemoimmunotherapy in Older Patients with CLL
Read More
Page 57 of 244
Results 561 - 570 of 2438